New Age Alpha Advisors LLC purchased a new position in DaVita Inc. (NYSE:DVA - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 11,915 shares of the company's stock, valued at approximately $1,782,000.
Other institutional investors and hedge funds also recently bought and sold shares of the company. MML Investors Services LLC lifted its position in shares of DaVita by 1.3% in the 3rd quarter. MML Investors Services LLC now owns 5,300 shares of the company's stock valued at $869,000 after acquiring an additional 68 shares in the last quarter. Exchange Traded Concepts LLC lifted its holdings in shares of DaVita by 8.3% in the fourth quarter. Exchange Traded Concepts LLC now owns 891 shares of the company's stock valued at $133,000 after purchasing an additional 68 shares in the last quarter. Impact Partnership Wealth LLC boosted its position in shares of DaVita by 3.7% in the fourth quarter. Impact Partnership Wealth LLC now owns 1,941 shares of the company's stock worth $290,000 after buying an additional 70 shares during the period. Contravisory Investment Management Inc. grew its holdings in shares of DaVita by 1.2% during the fourth quarter. Contravisory Investment Management Inc. now owns 6,082 shares of the company's stock valued at $910,000 after buying an additional 73 shares in the last quarter. Finally, Nilsine Partners LLC raised its position in DaVita by 0.8% during the fourth quarter. Nilsine Partners LLC now owns 11,160 shares of the company's stock valued at $1,669,000 after buying an additional 92 shares during the period. 90.12% of the stock is owned by institutional investors and hedge funds.
DaVita Stock Performance
Shares of DVA stock traded down $4.37 during trading hours on Friday, reaching $149.37. 1,009,511 shares of the company's stock were exchanged, compared to its average volume of 811,855. DaVita Inc. has a fifty-two week low of $125.64 and a fifty-two week high of $179.60. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18. The stock has a market capitalization of $11.95 billion, a P/E ratio of 13.91, a P/E/G ratio of 1.07 and a beta of 1.04. The business has a fifty day moving average price of $155.75 and a 200-day moving average price of $157.28.
DaVita (NYSE:DVA - Get Free Report) last released its earnings results on Thursday, February 13th. The company reported $2.24 EPS for the quarter, beating the consensus estimate of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. Analysts predict that DaVita Inc. will post 10.76 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research firms have weighed in on DVA. Cowen reiterated a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. StockNews.com downgraded shares of DaVita from a "buy" rating to a "hold" rating in a research note on Wednesday. Sanford C. Bernstein set a $184.00 price objective on DaVita in a research report on Friday, February 21st. Finally, Barclays upped their target price on DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research report on Tuesday, February 18th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $166.33.
Get Our Latest Analysis on DVA
DaVita Profile
(
Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Articles
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
